Evaluating the Safety, Tolerability, and Immunogenicity of a Tetravalent Dengue Vaccine (V180) in Healthy Adults Who Previously Received a Live-Attenuated Tetravalent Vaccine (TV003 or TV005)
- Conditions
- Dengue
- Interventions
- Biological: PlaceboBiological: V180Biological: Alhydrogel™
- First Posted Date
- 2015-05-21
- Last Posted Date
- 2016-04-04
- Target Recruit Count
- 20
- Registration Number
- NCT02450838
- Locations
- 🇺🇸
University of Vermont Medical Center, Burlington, Vermont, United States
🇺🇸University of Vermont Vaccine Testing Center, Burlington, Vermont, United States
🇺🇸Center for Immunization Research, Johns Hopkins School of Public Health, Baltimore, Maryland, United States
Xenodiagnosis After Antibiotic Treatment for Lyme Disease
- Conditions
- Lyme Disease
- Interventions
- Procedure: Skin biopsyProcedure: Blood drawDevice: Xenodiagnosis
- First Posted Date
- 2015-05-18
- Last Posted Date
- 2024-06-03
- Target Recruit Count
- 72
- Registration Number
- NCT02446626
- Locations
- 🇺🇸
Tufts Medical Center, Boston, Massachusetts, United States
🇺🇸Stony Brook University (State University of New York), Stony Brook, New York, United States
🇺🇸New York Medical College, Valhalla, New York, United States
Evaluating the Safety and Protective Efficacy of a Single Dose of a Trivalent Live Attenuated Dengue Vaccine to Protect Against Infection With DENV-2
- Conditions
- Dengue
- Interventions
- Biological: Recombinant live attenuated trivalent dengue vaccineBiological: PlaceboBiological: rDEN2Δ30-7169 vaccine
- First Posted Date
- 2015-05-05
- Last Posted Date
- 2018-02-28
- Target Recruit Count
- 24
- Registration Number
- NCT02433652
- Locations
- 🇺🇸
University of Vermont, Burlington, Vermont, United States
🇺🇸Center for Immunization Research (CIR), Johns Hopkins School of Public Health, Baltimore, Maryland, United States
Ebola Virus Disease Survivors: Clinical and Immunologic Follow-up
- Conditions
- Ebola Virus Disease
- First Posted Date
- 2015-05-01
- Last Posted Date
- 2022-10-10
- Target Recruit Count
- 4043
- Registration Number
- NCT02431923
- Locations
- 🇱🇷
CH Rennie Hospital, Kakata, Liberia
🇺🇸National Institutes of Health Clinical Center, Bethesda, Maryland, United States
🇱🇷JFK Hospital, Monrovia, Liberia
Evaluating the Safety and Immunogenicity of PENNVAX®-GP DNA Vaccine and IL-12 Plasmid, Delivered Via Intradermal or Intramuscular Electroporation in Healthy, HIV-Uninfected Adults
- Conditions
- HIV Infections
- Interventions
- Biological: PENNVAX®-GP HIV-1 DNA vaccineBiological: PlaceboBiological: Interleukin-12 (IL-12) DNA adjuvant
- First Posted Date
- 2015-05-01
- Last Posted Date
- 2021-10-15
- Target Recruit Count
- 94
- Registration Number
- NCT02431767
- Locations
- 🇺🇸
Vanderbilt Vaccine (VV) CRS, Nashville, Tennessee, United States
🇺🇸Seattle Vaccine and Prevention CRS, Seattle, Washington, United States
🇺🇸University of Rochester Vaccines to Prevent HIV Infection CRS, Rochester, New York, United States
Autologous Polyclonal Tregs for Lupus
- Conditions
- Lupus Erythematosus, CutaneousLupus Erythematosus, DiscoidLupus Erythematosus, Systemic
- Interventions
- Biological: Ex vivo Expanded Human Autologous Polyclonal Regulatory T Cells
- First Posted Date
- 2015-04-28
- Last Posted Date
- 2019-11-12
- Target Recruit Count
- 1
- Registration Number
- NCT02428309
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
Pretomanid in Adults With Hepatic Impairment
- First Posted Date
- 2015-04-21
- Last Posted Date
- 2025-03-05
- Target Recruit Count
- 14
- Registration Number
- NCT02422524
- Locations
- 🇺🇸
Saint Louis University Center for Vaccine Development, Saint Louis, Missouri, United States
🇺🇸Duke University School of Medicine - Duke Clinical Research Institute - Duke Clinical Research Unit, Durham, North Carolina, United States
Pharmacokinetics of Two Intravaginal Rings (IVRs) Containing Different Dose Strengths of Vicriviroc (MK-4176) and MK-2048
- Conditions
- HIV Infections
- Interventions
- Drug: MK-2048A IVR (Low Dose)Drug: MK-2048A IVR (Original Dose)
- First Posted Date
- 2015-04-17
- Last Posted Date
- 2021-11-11
- Target Recruit Count
- 19
- Registration Number
- NCT02419456
- Locations
- 🇺🇸
Bridge HIV CRS, San Francisco, California, United States
NIAID Clinical Center Genomics Opportunity Protocol
- Conditions
- Immune Disorders
- First Posted Date
- 2015-04-16
- Last Posted Date
- 2023-03-16
- Target Recruit Count
- 139
- Registration Number
- NCT02417766
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Evaluating the Safety, Tolerability, and Effect of a Human Monoclonal Antibody (VRC01) on Markers of HIV Persistence in HIV-Infected Adults Receiving Antiretroviral Therapy (ART)
- Conditions
- HIV Infections
- Interventions
- Biological: VRC01Biological: Placebo
- First Posted Date
- 2015-04-08
- Last Posted Date
- 2021-11-05
- Target Recruit Count
- 40
- Registration Number
- NCT02411539
- Locations
- 🇺🇸
Northwestern University CRS, Chicago, Illinois, United States
🇺🇸Massachusetts General Hospital CRS (MGH CRS), Boston, Massachusetts, United States
🇺🇸University of Washington AIDS CRS, Seattle, Washington, United States